New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of Cholecalciferol 7000 IU Tablets under the provisions of the Drugs (Prices Control) Order (DPCO), 2013.

The formulation by Windlas Biotech Limited/Eris Lifesciences Limited has been priced at Rs. 8.93 per tablet, excluding Goods and Services Tax (GST), wherever applicable.

The price fixation has been undertaken in exercise of the powers conferred by paragraphs 5, 11 and 15 of the DPCO, 2013, read with S.O. 1394(E) dated May 30, 2013, S.O. 5249(E) dated November 11, 2022, and S.O. 3516(E) dated June 30, 2026.

Also Read:NPPA Grants Biodeal's Midazolam Nasal Spray 5 Year Price Control Exemption

The notification stated,

"In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 and S.O. 3516(E) dated 30th June, 2026 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA) has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Sl. No.

Name of the Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

1

Cholecalciferol Tablets

Each uncoated chewable tablet contains: Cholecalciferol IP 7000 IU

1 Tablet

M/s Windlas Biotech Limited/M/s Eris Lifesciences Limited

8.93

The notification further added,

a) The manufacturer, as mentioned in column (5) of the table above, of formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price not exceeding the price as specified in column (6) of the table above.
b) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
c) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
Also Read:NPPA Fixes Retail Prices of 34 Drug Formulations Including Gemcitabine, Carbimazole
d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

To view the official notice, click the link below:

https://medicaldialogues.in/pdf_upload/2026/11/06/277617-482491.pdf
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Susmita Roy

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .